课题基金 / 基金详情

UAB CFRC Administrative Core

UAB CFRC Administrative Core
UAB CFRC 行政核心
批准号:
10673354
负责人:
David M. Bedwell
金额:
$13.96万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
未结题
起止时间:
2007-04-01 至 2028-04-30

项目摘要

项目成果

David M. Bedwell的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结/摘要 UAB囊性纤维化研究和翻译核心中心行政核心负责 全面管理和协调生物医学研究核心、试点和可行性计划,以及 强化计划。行政核心由Bedwell博士(P30主任)Birket和所罗门指导 (副主任),沿着Rowe博士(副主任)的持续参与, 旨在确保与CF基金会的倡议建立无缝的合作伙伴关系。Guimbellot博士将担任 与Birket博士一起担任丰富计划的联合主任。在这一领导下, 经验丰富的研究管理和行政团队(包括Jeffrey Allison先生,中心 行政主任和科学事务项目主任艾米丽Falk-Libby博士),核心将继续 成功地支持CF中心在即将到来的资助周期的目标:1)建立全面的科学 UAB P30 CF中心的方向,并确保持续的贡献和发展成为最相关的 疾病领域,包括基因疗法的应用(例如,指挥通信之间的 行政核心,P30调查员,中心内部咨询委员会成员,和/或 外部咨询委员会的外部顾问,审查中心的活动并确定研究方向 2)促进P30所有组成部分的目标(例如,确定核心资源的优先次序, 新设备的采购,以实现最佳利用,监督新的最先进的核心研究空间, 设施,协调培训和专业发展活动,维护中心网站, 监督成员,建立生物医学核心研究基地,并监测其生产力, 支持内部和外部合作,管理COVID-19的成功运营),以及3) 将P30组件与其他UAB NIH中心(例如,促进和分享其创新资源 并与其他中心领导沟通,如临床和转化科学中心 (UAB的CTSA网站),NIDDK-糖尿病研究和培训中心,NIDDK-营养肥胖研究 中心和NIDDK-肝肾纤维囊性疾病核心中心),以确定持续的机会, 多学科合作。此外,特别是为了支持该中心的丰富和试点工作, 可行性方案,行政核心将继续确定和整合通过以下方式提供的资源: 该机构最大限度地提高学员的成功和过渡到独立的初级教师,以及申请 其建立的,强大的机制,征求,审查和监督P30试点申请,以促进新的 对CF科学的重要贡献。总的来说,行政核心的目标是以最佳方式 促进CF P30中心的协同作用和进步。
英文摘要
PROJECT SUMMARY/ABSTRACT The UAB Cystic Fibrosis Research and Translation Core Center Administrative Core is responsible for the overall administration and coordination of the Biomedical Research Cores, Pilot & Feasibility Program, and Enrichment Program. The Administrative Core is directed by Drs. Bedwell (P30 Director) Birket, and Solomon (Associate Directors), along with continued involvement from Dr. Rowe (Associate Director) that additionally serves to assure a seamless partnership with initiatives from the CF Foundation. Dr. Guimbellot will serve as Co-Director of the Enrichment Program with Dr. Birket. Under this leadership, with assistance from the experienced Research Management and Administrative Team (including Mr. Jeffrey Allison, Center Administrative Director, and Dr. Emily Falk-Libby, Program Director-Scientific Affairs), the Core will continue to successfully support CF Center goals in the upcoming funding cycle by: 1) Establishing the overall scientific direction of the UAB P30 CF Center and ensuring continued contributions and growth into the most relevant disease areas, including application of genetic therapies (e.g., directing communications between the Administrative Core, P30 investigators, members of the Center’s active Internal Advisory Board, and/or external consultants on its External Advisory Board to review Center activities and identify research directions and opportunities), 2) Facilitating the objectives of all P30 components (e.g., prioritizing Core resources and new equipment acquisition for optimal utilization, overseeing new state-of-the-art Core research space and facilities, coordinating training and professional development activities, maintaining a Center website, overseeing membership, building the Biomedical Core research base and monitoring its productivity, supporting internal and external collaborations, managing successful operations in COVID-19), and 3) Integrating P30 components with other UAB NIH Centers (e.g., promoting and sharing its innovative resources and communicating with other Center leadership such as the Center for Clinical and Translational Science (UAB’s CTSA site), NIDDK-Diabetes Research and Training Center, NIDDK-Nutrition Obesity Research Center, and NIDDK-Hepatorenal Fibrocystic Diseases Core Center) to identify continued opportunities for multidisciplinary collaboration. In addition, specifically in support of the Center’s Enrichment and Pilot & Feasibility Programs, the Administrative Core will continue to identify and integrate resources offered through the Institution to maximize trainee success and transition to independence for junior faculty as well as to apply its established, robust mechanisms for solicitation, review, and oversight of P30 pilot applications to foster new and important contributions to CF science. Overall, it is the goal of the Administrative Core to optimally promote synergy and progress within the CF P30 Center.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
New Nonsense Suppression Drugs to Treat MPS I
Mechanism of Eukaryotic Translation Termination
Suppression of the Idua-W402X mutation in an MPS I-H mouse
Suppression of the Idua-W402X mutation in an MPS I-H mouse
海外基金